Two separate laboratory breakthroughs have produced RNA molecules that can build copies of themselves or assemble functional structures without any help from proteins or DNA. These results offer the ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...